• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in autoimmune vasculitis

byPaul ZhouandMichael Pratte
June 2, 2021
in Chronic Disease, Nephrology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Reduced-dose glucocorticoid plus rituximab regimen was non-inferior compared to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in ANCA-associated vasculitis 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis is a group of multi-system autoimmune small and medium-sized vessel vasculitides with a prevalence of 4.6-18.4 cases per 100,000 individuals worldwide. Current standard therapies for induction of ANCA-associated vasculitis include high-dose glucocorticoids plus either cyclophosphamide or rituximab, which is associated with a high mortality rate and significant adverse events. In this phase 4, open-label randomized clinical trial, 140 patients with newly diagnosed ANCA-associated vasculitis were recruited to evaluate and compare of the efficacy and potential adverse effects of reduced-dose glucocorticoid plus rituximab regimen with high-dose glucocorticoid plus rituximab regimen for induction of ANCA-associated vasculitis remission. At 6 months after initiating treatment, 71% of the patients in the reduced-dose group achieved ANCA-associated vasculitis remission, while 69.2% in the high-dose achieved disease remission. Two deaths were reported in the reduced-dose group, and there were three deaths in the high-dose group, without any statistically significant difference between the two treatment regimen groups. The study does however have  limitations, primarily the cofounding that comes with an open-label trial. It was difficult to blind the effects of high-dose glucocorticoid as patients can easily notice the changes in their appearance and blood tests.

Click to read the study in JAMA 

Relevant Reading: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

In-Depth [Randomized clinical trial]: In this randomized clinical trial with 140 patients, 70 patients were assigned to the high-dose group (high-dose glucocorticoid plus rituximab), and the other half were randomly assigned to the reduced-dose group (reduced-dose glucocorticoid plus rituximab). The difference between the two groups for achieving disease remission in 6 months was 1.8 percentage points (1-sided 97.5% Confidence Interval, -13.7 to infinity) which met the noninferiority criterion (P=0.003 for noninferiority). The main adverse event was death of patients. The difference of reported deaths in the two groups was −1.7% (95% CI, −4.7% to 8.2%, P=0.67) with no statistically significant difference.

RELATED REPORTS

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

Prenatal Systemic Glucocorticoid Exposure and an Increased Risk of Future Mental Disorders

Crinecerfont decreases glucocorticoid use in adults with congenital adrenal hyperplasia

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ANCAANCA-associated vasculitisglucocorticoid
Previous Post

Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia

Next Post

Critically ill COVID-19 patients in Africa may have worse outcomes compared to global rates  

RelatedReports

Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission

June 9, 2025
Prenatal Systemic Glucocorticoid Exposure and an Increased Risk of Future Mental Disorders
StudyGraphics

Prenatal Systemic Glucocorticoid Exposure and an Increased Risk of Future Mental Disorders

January 16, 2025
Palliative chemotherapy associated with more ICU treatment at end-of-life
Chronic Disease

Crinecerfont decreases glucocorticoid use in adults with congenital adrenal hyperplasia

October 7, 2024
Endocrinology

Crinecerfont facilitates glucocorticoid dose reduction in pediatric congenital adrenal hyperplasia

October 7, 2024
Next Post
Brain drain from sub-Saharan Africa to US worsening

Critically ill COVID-19 patients in Africa may have worse outcomes compared to global rates  

Digital imaging detects sight-threatening retinopathy of prematurity

Very preterm birth or very low birth weight associated with lower intelligence among young adults

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Comorbid cancer and systemic therapy may influence immune response to SARS-CoV-2 among patients and health care workers

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.